新华制药：磷酸奥司他韦干混悬剂获药品注册证书

Core Viewpoint - Xinhua Pharmaceutical has received the drug registration certificate for Oseltamivir Phosphate Dry Suspension from the National Medical Products Administration, indicating a significant advancement in its product offerings for influenza treatment and prevention [1] Group 1: Product Approval - The drug is approved for the treatment of influenza A and B in patients aged 2 weeks and older [1] - It can also be used for the prevention of influenza A and B in individuals aged 1 year and above [1]